Aniridia is a devastating ocular disease requiring intensive eye care, social and community support from birth and throughout an individual’s lifetime.

Recent News

© 2019 – University of Cologne – Webdesign by Effect Group Ltd.

Management Committee / Working Groups Meeting (MC/WG3) – Lisbon, 27th and 28th February 2020

Management Committee / Working Groups Meeting (MC/WG3) – Lisbon, 27th and 28th February 2020

AniridiaNet COST Actions #18116 members and participants got together for the Action’s 3rd MC/WG meeting taking place at the Molecular Medicine Institute in Lisbon, last 27th and 28th February 2020, coinciding with Rare Disease Day []. A highly successful meeting that gathered ophthalmologist, researchers, trainees, industry and patient’s organizations to discuss recent advancements and to foster collaborations for further growth and research in the field of aniridia. Culture and assessment of LSC, clinical multicentre studies, harmonized clinical protocols, aniridia pathophysiology, post-transplant immunosuppression and MSCs for eye diseases are some of the topics covered during this networking event. Find out more in meeting minutes HERE. This meeting owes its success to all its enthusiastic members devoting their expertise and much of their time to provide the action with outstanding resources to stimulate collaboration with the aim of improving aniridia management through evidence-based research and harmonized clinical protocols. We would like to express many thanks to all participants for coming and in particular to our Portuguese members for their invaluable help with the organization.

No Comments

Post A Comment